Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 415-424

  Weber, Lutz T ^a   Armstrong, Victor W ^b   Shipkova, Maria ^c   Feneberg, Reinhard ^a   Wiesel, Manfred ^a   Mehls, Otto ^a   Zimmerhackl, Lothar B ^d   Oellerich, Michael ^b   Tönshoff, Burkhard ^a   Boswald M ^e   Ruder, H ^e   Rascher, W ^e   Schroder M ^e   Dippell, J ^e   Staskewitz, A ^e   Kirste, G ^e   Brandis, M ^e   Zimmerhackl, L B ^e   Weber, L T ^e   Tonshoff B ^e   John, U ^e   Misselwitz, J ^e   Querfeld, U ^e   Greiner, C ^e   Klaus, G ^e   Seyberth, H W ^e   Klare, B ^e   Kuwertz Broking E ^e   Bulla, M ^e   Holder, M ^e   Leichter, H ^e   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c KATHARINENHOSPITAL   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e University Children's Hospital ^*

Author keywords

Absorption profiling; Children; Cyclosporin A; Renal transplantation

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

EID: 20844456084     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00012     Document Type: Article

References (29)

1. Kahan BD. Recommendations concerning the introduction of generic formulations of cyclosporine. Transplant Proc. 1999;31:1634.
2. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit. 2002;24:40-46.
3. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
4. Caruso R, Perico N, Cattaneo D, et al. In renal transplant recipients whole blood calcineurin activity is not predicted by cyclosporine blood levels. Clin Chem. 2001;47:1679-1697.
5. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation. 1999;68:55-62.
6. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol. 2001;12:828-833.
7. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73(9 Suppl):S3-11.
8. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003;75:2086-2090.
9. Levy G, Thervet E, Lake J, et al. Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73(9 Suppl):S12-18.
10. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986;11:107-132.
11. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet. 1997;32:481-495.
12. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
13. Weber LT, Shipkova M, Armstrong VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem. 2002;48:517-525.
14. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411-422.
15. Good IJ. When batterer turns murderer. Nature. 1995;375:541.
16. Matthews RAJ. Base-rate errors and rain forecasts. Nature. 1996;382:766.
17. Einecke G, Mai I, Diekmann F, et al. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. Transplant Proc. 2002;34:1738-1739.
18. Staskewitz A, Kirste G, Tonshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation. 2001;71:638-644.
19. Levy GA. C2 monitoring strategy for optimizing cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 2001;15:279-290.
20. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34:571-590.
21. Hoyer PF, Vester U. Refining immunosuppressive protocols in pediatric renal transplant recipients. Transplant Proc. 2001;33:3587-3589.
22. Dunn S, Falkenstein K, Cooney G. Neoral C(2) monitoring in pediatric liver transplant recipients. Transplant Proc. 2001;33:3094-3095.
23. Kovarik JM, Hoyer PF, Ettenger R, et al. Cyclosporine absorption profiles in pediatric kidney and liver transplant patients: Implications for therapeutic drug monitoring. Pediatr Nephrol. 2003;18:1275-1279.
24. Trompeter R, Fitzpatrick M, Hutchinson C, et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant. 2003;7:282-288.
25. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr postdose levels (C2). Transplantation. 2002;73:953-959.
26. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003;76:903-908.
27. Weber LT, Höcker B, Armstrong VW, et al. Is there an influence of MDR-1 C3435T-polymorphism or of CYP3A4 promotor polymorphism on the pharmacokinetics of cyclosporin A in pediatric renal transplant recipients? [abstract]. Pediatr Nephrol. 2002;17:C136.
28. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248-260.
29. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003;13:89-95.